Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 33Terminated 27Recruiting 12Active not recruiting 8Unknown 5Withdrawn 3Suspended 1

Sponsor Class

OTHER 11INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Hemangiosarcoma 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × spartalizumab × Clear all
NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Novartis

Phase 1 Withdrawn
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡